Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
Tracer Biotechnologies has announced a multi-year agreement with AstraZeneca (AZN) to implement its circulating tumor DNA (ctDNA) monitoring technology in clinical trials. The company's proprietary platform, based on digital PCR technology, offers a cost-effective and precise alternative to traditional radiographic imaging for cancer monitoring. The platform specializes in tumor-informed ctDNA detection, enabling more frequent and accurate assessment of treatment response and disease progression in cancer patients.
Tracer Biotechnologies ha annunciato un accordo pluriennale con AstraZeneca (AZN) per implementare la sua tecnologia di monitoraggio del DNA tumorale circolante (ctDNA) negli studi clinici. La piattaforma proprietaria dell'azienda, basata su tecnologia PCR digitale, offre un'alternativa economica e precisa all'imaging radiografico tradizionale per il monitoraggio del cancro. La piattaforma si specializza nella rilevazione di ctDNA informato dal tumore, consentendo una valutazione più frequente e accurata della risposta al trattamento e della progressione della malattia nei pazienti oncologici.
Tracer Biotechnologies ha anunciado un acuerdo a varios años con AstraZeneca (AZN) para implementar su tecnología de monitoreo de ADN tumoral circulante (ctDNA) en ensayos clínicos. La plataforma propietaria de la empresa, basada en tecnología de PCR digital, ofrece una alternativa precisa y rentable a la imagen radiográfica tradicional para el monitoreo del cáncer. La plataforma se especializa en la detección de ctDNA informado por el tumor, lo que permite una evaluación más frecuente y precisa de la respuesta al tratamiento y de la progresión de la enfermedad en pacientes con cáncer.
Tracer Biotechnologies는 임상 시험에서 순환 종양 DNA(ctDNA) 모니터링 기술을 구현하기 위해 AstraZeneca (AZN)와 다년 계약을 체결했다고 발표했습니다. 회사의 독점 플랫폼은 디지털 PCR 기술 기반으로 하며, 암 모니터링을 위해 기존의 방사선 영상에 대한 비용 효율적이고 정밀한 대안을 제공합니다. 이 플랫폼은 종양 정보 ctDNA 검출에 특화되어 있어 암 환자에서 치료 반응 및 질병 진행을 더 빈번하고 정확하게 평가할 수 있게 합니다.
Tracer Biotechnologies a annoncé un accord pluriannuel avec AstraZeneca (AZN) pour mettre en œuvre sa technologie de surveillance de l'ADN tumoral circulant (ctDNA) dans des essais cliniques. La plateforme propriétaire de l'entreprise, basée sur la technologie PCR numérique, offre une alternative économique et précise à l'imagerie radiographique traditionnelle pour le suivi du cancer. La plateforme se spécialise dans la détection de ctDNA informée par la tumeur, permettant une évaluation plus fréquente et précise de la réponse au traitement et de la progression de la maladie chez les patients atteints de cancer.
Tracer Biotechnologies hat eine mehrjährige Vereinbarung mit AstraZeneca (AZN) angekündigt, um seine Technologie zur Überwachung von zirkulierender Tumor-DNA (ctDNA) in klinischen Studien zu implementieren. Die proprietäre Plattform des Unternehmens, die auf digitaler PCR-Technologie basiert, bietet eine kostengünstige und präzise Alternative zur herkömmlichen radiographischen Bildgebung für die Krebsüberwachung. Die Plattform spezialisiert sich auf die Tumor-informierte ctDNA-Detektion, die eine häufigere und genauere Beurteilung der Behandlungsergebnisse und des Krankheitsverlaufs bei Krebspatienten ermöglicht.
- Strategic partnership with major pharmaceutical company AstraZeneca
- Multi-year agreement ensures stable revenue stream
- Technology offers cost-effective alternative to traditional cancer monitoring methods
- None.
Insights
The collaboration marks a significant advancement in cancer monitoring technology. Tracer's ctDNA platform represents a paradigm shift from traditional imaging-based monitoring to more precise molecular detection methods. The technology's ability to detect minimal residual disease and monitor treatment response through blood samples offers several advantages: earlier detection of disease progression, more frequent monitoring capabilities and potentially reduced healthcare costs compared to traditional radiographic imaging.
The platform's utilization of digital PCR technology suggests high sensitivity and specificity in detecting tumor DNA fragments in blood. This could be particularly valuable for AstraZeneca's clinical trials, enabling more rapid and accurate assessment of drug efficacy. The cost-effectiveness and scalability of the platform could accelerate drug development timelines and improve patient outcomes through more timely treatment adjustments.
This partnership could strengthen AstraZeneca's oncology clinical trial capabilities and potentially accelerate their drug development timeline. The adoption of Tracer's technology may lead to reduced clinical trial costs and improved efficiency in assessing drug efficacy. While financial terms weren't disclosed, the multi-year nature of the agreement suggests a significant commitment from both parties.
The collaboration aligns with the growing trend toward liquid biopsy and precision medicine in oncology, a market projected to see substantial growth. For AstraZeneca, this technology could provide a competitive advantage in drug development by enabling more frequent and precise monitoring of treatment responses, potentially leading to faster drug approvals and market entry.
The agreement will enable AstraZeneca to use Tracer’s circulating tumor DNA (ctDNA) monitoring technology for clinical trials. Tracer has developed a proprietary platform for tumor-informed ctDNA detection based on digital polymerase chain reaction (PCR). Tracer’s platform optimizes ctDNA detection, enabling cost-effective, precise, and scalable testing for patients as an alternative to radiographic imaging.
“We are entering a new era of oncology where patients will no longer have to wait for costly and imprecise radiographic scans to assess treatment and disease progression,” said Mark Kaganovich, CEO of Tracer Biotechnologies. “We are proud to work with AstraZeneca to leverage frequent, precise, and cost-effective ctDNA measurement for minimal residual disease detection and treatment response monitoring.”
About Tracer Biotechnologies
Tracer Biotechnologies is a next-generation diagnostics company. Tracer is the only ultrasensitive ctDNA assay for Molecular Response surveillance. Combining tumor-informed personalization with dPCR allows Tracer to offer cost-effective assays for an unlimited number of timepoints on a study. The Tracer assay is available for blood and urine.
For more information, please visit https://tracerbio.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212366378/en/
Source: Tracer Biotechnologies
FAQ
What is the purpose of AstraZeneca's (AZN) partnership with Tracer Biotechnologies?
How does Tracer Biotechnologies' ctDNA monitoring technology differ from traditional cancer monitoring methods?
What technology does Tracer Biotechnologies use for cancer monitoring?
What are the benefits of Tracer's ctDNA monitoring system for AZN's clinical trials?
